Summit Therapeutics PLC
$ 14.94
-2.86%
05 Mar - close price
- Market Cap 11,925,232,000 USD
- Current Price $ 14.94
- High / Low $ 15.15 / 14.67
- Stock P/E N/A
- Book Value 0.85
- EPS -1.44
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.15 %
- ROE -2.06 %
- 52 Week High 36.91
- 52 Week Low 13.83
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$31.29
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-10-28 | 2025-08-11 | 2025-04-29 | 2025-02-24 | 2024-10-30 | 2024-08-06 | 2024-05-01 | 2024-02-20 | 2023-11-07 | 2023-08-09 | 2023-05-11 |
| Reported EPS | -0.3908 | -0.2315 | -0.12 | -0.0677 | -0.07 | -0.08 | -0.09 | -0.06 | -0.04 | -0.03 | -0.02 | -1.43 |
| Estimated EPS | -0.08 | -0.1032 | -0.09 | -0.0682 | -0.08 | -0.07 | -0.06 | -0.06 | -0.05 | None | None | -1.43 |
| Surprise | -0.3108 | -0.1283 | -0.03 | 0.0005 | 0.01 | -0.01 | -0.03 | 0 | 0.01 | 0 | 0 | 0 |
| Surprise Percentage | -388.5% | -124.3217% | -33.3333% | 0.7331% | 12.5% | -14.2857% | -50% | 0% | 20% | None% | None% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1217 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SMMT
2026-03-04 21:52:51
Summit Therapeutics (SMMT) shares fell 6.3% following its full-year 2025 report which showed a wider net loss of US$1.08 billion and higher per-share losses, alongside a US$102.02 million ESOP shelf filing. Despite these financial setbacks, the company emphasized its strong cash position, debt-free balance sheet, and progress in 15 Phase 3 trials for its cancer therapy ivonescimab, including an accepted FDA biologics license application. Investors are weighing the significant cash burn and unprofitability against the potential future success of ivonescimab, with varied opinions on the company's fair value.
2026-03-03 17:51:52
Summit Therapeutics (SMMT) has seen strong multi-year gains but recent pullbacks. The company currently scores 2/6 on Simply Wall St's valuation framework. A Discounted Cash Flow (DCF) analysis suggests SMMT is undervalued by 90.1%, while a Price-to-Book (P/B) ratio indicates it is overvalued compared to its industry and fair ratio.
2026-03-03 07:52:51
Summit Therapeutics (SMMT) finished 2025 with robust financial health, reporting $713.4 million in cash and no debt, despite increased non-GAAP operating expenses due to significant investment in its Harmony 3 and Harmony 7 clinical trials. The company is primarily focused on the development of ivonescimab, with a key interim analysis for squamous lung cancer expected in Q2 2026. However, regulatory approval faces uncertainty as the FDA requires statistically significant overall survival data for marketing authorization.
2026-03-03 07:52:51
Summit Therapeutics Inc. (SMMT) is advancing its ivonescimab development for non-small cell lung cancer (NSCLC) and colorectal cancer through multiregional Phase III clinical trials, and has engaged GORTEC to activate European sites. The company also reported a net loss of $347.2 million in 2025 but maintains a strong cash position. Summit's lead candidate, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF for solid tumors.
2026-03-03 07:51:52
Summit Therapeutics (SMMT) finished 2025 with robust financial health, boasting approximately $713.4 million in cash and no debt. The company increased its investment in clinical trials, particularly for ivonescimab, despite rising non-GAAP operating expenses. Regulatory challenges remain, as the FDA requires statistically significant overall survival data for marketing authorization in certain lung cancer indications, introducing uncertainty to approval timelines.
2026-03-03 03:53:30
This article provides a detailed financial overview of Summit Therapeutics Inc (SMMT) for fiscal year 2025, including income statement, balance sheet, and cash flow data. It highlights the company's financial health, key metrics like negative net income, diluted EPS, and free cash flow, alongside its Piotroski F-Score and earnings quality. The report indicates weak financial health and accrual-driven earnings, with an estimated cash runway of 8 months.
